B

Biljana Bijelić

About

Detail

Belgrade, Serbia

Contact Biljana regarding: 
work
Full-time jobs
Starting at USD1k/month
Flexible work
Starting at USD6.25/hour

Timeline


work
Job
school
Education
folder
Project

Résumé


Jobs verified_user 0% verified
  • ICON Clinical Research
    Site Activation Lead
    ICON Clinical Research
    Sep 2021 - Current (4 years 10 months)
    Lead clinical trial start-up activities by understanding the clients' objectives and assist them in the development of the plan for country and site distribution. Prepare and contribute to client and project specific site activation strategy and site activation plan and work cross-functionally to ensure that the sites and countries chosen optimize opportunities for successful delivery of the project. Knowledgeable in the areas of clinical trial operations, meeting regulatory and ICON guidelines, and displaying project management skills to optimize performance and collaboration to ensure successful study outcomes. Study Start up experience leading sponsor initiatives such as kick-off meetings, bid defenses, project update and status calls, a
  • A
    RSM and Regulatory and Start Up Specialist II(South East Europe)
    Allergan Abbvie
    Sep 2017 - Sep 2021 (4 years 1 month)
  • A
    RBM / Reg Aff. Specialist
    Allergan Abbvie
    Jun 2017 - Sep 2021 (4 years 4 months)
    Responsible for monitoring all types of clinical trials; assuring adherence to Good Clinical Practices and all other applicable laws and regulations, investigator integrity, and compliance with all study procedures, management of clinical trials. Primary responsibility site management and performance (including documentation) according to ICH guidelines (and country specific guidelines and government regulations), as well as FDA regulations (state and local laws), GCPs, and SOPs. Site management activities included all in house and on-site monitoring for all visit types. Collaboration with the Project managers and Line Manager to provide input into clinical management of a clinical study. Data quality assurance: In-depth review of subject-l
  • Q
    Regulatory and Start Up Specialist II / Site ID, Feasibility, Capability
    Quintiles IMSIQVIA
    Jun 2015 - Sep 2017 (2 years 4 months)
    Acting as a key point of contact with the sponsor and internal team regarding all Regulatory activities for the assigned study. Overseeing all associates assigned to work on the regulatory, ethics and essential document portion of the study. Assuming responsibility on deliverables at the project level. The planning, coordination and oversight of all processes involved in gaining approvals required in each country for a clinical trial to commence. This will include competent authority approvals, ethics committee approvals, import license approvals, radiation approval, tissue/biological sample export and any other local approvals required in a given country. Experienced clinical research professional to specialize in clinical trial intelligen
  • Q
    Clinical Trial Manager
    QuintilesGFR department(Sponsor dedicated)
    Jun 2013 - Jun 2015 (2 years 1 month)
    Monitoring of the clinical trial and conducting source data verification of the case record forms using paper based and/or EDC Systems in accordance with the protocol and trial specific monitoring/trial product reference manuals. Conducting Site ID and study start up meetings and study, center closure center closure. Organizing and maintenance of the Investigator Files, Trial and Site Master files. Training trial staff or other monitors on trial related procedures, EDC or SOP's.
  • O
    Senior Clinical Trial Coordinator Submissions – Regulatory
    OptumInsight
    May 2010 - Jun 2013 (3 years 2 months)
    Monitoring of the clinical trial and conducting source data verification of the case record forms using paper based and/or EDC Systems in accordance with the protocol and trial specific monitoring/trial product reference manuals. Conducting Site ID and study start up meetings and study, center closure center closure. Organizing and maintenance of the Investigator Files, Trial and Site Master files. Training trial staff or other monitors on trial related procedures, EDC or SOP's.
  • O
    SMA/ Country Expert
    OptumInsight
    May 2008 - Dec 2010 (2 years 8 months)
  • P
    Main Pharmacist
    PRIMA pharmacy
    May 2000 - May 2008 (8 years 1 month)
Education verified_user 0% verified
  • Zeppelin Labs
    ACRP certified GCP Lecturer
    Zeppelin Labs
    Feb 2022 - May 2023 (1 year 4 months)
  • U
    Master's degree
    University of Pharmacy, Belgrade, Serbia
    Oct 1992 - Jan 1998 (5 years 4 months)
    Primary Subject: Pharmacology and Pharmacovigilance-Oncology and Psychiatry
Projects (professional or personal) verified_user 0% verified
  • S
    Site Activation Lead
    Sep 2021 - Current (4 years 10 months)
    Phase: NIS. Responsibilities: Regions: EU, US and CANADA, MENA, APAC. Countries involved: Italy, France, UK, Canada, US, Spain, United Kingdom
  • G
    Glycogen Storage Disorder Type III (GSD III) Is a Serious, Rare, Metabolic Disease Characterized by Defective Glycogen D
    Sep 2021 - Current (4 years 10 months)
    Phase: N/A. Responsibilities: Regions: EU, APAC and Canada. Countries involved: France, Switzerland, Austria, Denmark, Australia, UK, Canada
  • G
    Global Site Activation Lead
    Sep 2021 - Current (4 years 10 months)
    A multicenter, open-label post authorization safety study to evaluate the effect of XXX infusion on serum potassium levels in GEP-NET patients eligible for XXX treatment (0050/0870)
  • A
    A multi-national, cross-sectional, non-interventional study being conducted to better understand the treatment experienc
    Sep 2021 - Jun 2022 (10 months)
    Phase: Phase III. Responsibilities: Regions: EU and US. Countries involved: US, EU, APAC, MENA
  • G
    Global Patient Registry to Monitor Long-term Safety and Effectiveness of XXX in Children and Adolescents with Severe Pri
    Sep 2021 - Jun 2022 (10 months)
    Phase: Phase IV. Responsibilities: Regions: EU (UK, Netherlands, Italy, Poland)
  • A
    A Multicentre Surveillance Study to Evaluate the Long-term Safety in Participants who Have Been Previously Treated with
    Sep 2021 - May 2022 (9 months)
    Phase: Phase IV. Responsibilities: Regions: US & EU. Countries involved (No. of sites still to be discussed):UK, France, Italy, Spain, Sweden, Poland, Germany, Austria and US
  • P
    Project in WE, APAC, US
    Apr 2008 - Feb 2026 (17 years 11 months)